Ziegler Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ziegler Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$6.57M	Sell	6,827 -158	-2%	-$150K	0.25%	137
2023 Q4	$6.13M	Sell	6,985 -302	-4%	-$249K	0.28%	82
2023 Q3	$6M	Sell	7,287 -332	-4%	-$261K	0.24%	147
2023 Q2	$5.47M	Sell	7,619 -444	-6%	-$342K	0.21%	164
2023 Q1	$6.63M	Sell	8,063 -132	-2%	-$99.6K	0.26%	144
2022 Q4	$5.91M	Sell	8,195 -136	-2%	-$100K	0.25%	142
2022 Q3	$5.74M	Sell	8,331 -2,337	-22%	-$1.47M	0.25%	143
2022 Q2	$6.31M	Sell	10,668 -309	-3%	-$201K	0.26%	141
2022 Q1	$7.67M	Sell	10,977 -745	-6%	-$471K	0.32%	120
2021 Q4	$7.4M	Sell	11,722 -558	-5%	-$343K	0.27%	136
2021 Q3	$7.43M	Sell	12,280 -222	-2%	-$138K	0.27%	133
2021 Q2	$6.98M	Sell	12,502 -502	-4%	-$254K	0.23%	151
2021 Q1	$6.15M	Buy	13,004 +12,558	+2,816%	+$6.11M	0.19%	173
2020 Q4	$215K	Buy	+446	New	+$241K	0.01%	416

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ziegler Capital Management's REGN Position: Q1 2024 in Review

Ziegler Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q1 2024, selling an estimated $150K and leaving 6,827 shares worth $6.57M. The position accounts for 0.25% of the portfolio, ranked #137.

Ziegler Capital Management first reported a position in REGN in Q4 2020 and has held it in 14 quarters since. The position peaked at $7.67M in Q1 2022. 1,310 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Ziegler Capital Management held 6,827 shares of Regeneron Pharmaceuticals worth $6.57M as of Q1 2024.
Ziegler Capital Management sold 158 Regeneron Pharmaceuticals shares in Q1 2024, an estimated $150K.
Regeneron Pharmaceuticals made up 0.25% of Ziegler Capital Management's portfolio in Q1 2024, its #137 holding.
Ziegler Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
Ziegler Capital Management's Regeneron Pharmaceuticals position peaked at $7.67M in Q1 2022.
1,310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Ziegler Capital Management's 13F filing for Q1 2024, filed 15 May 2024.